Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...
3don MSN
New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer
Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder ...
SurvivorNet on MSN
New approval means more bladder cancer patients can access powerful immunotherapy combination: What to know about Keytruda + Padcev
A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...
Muscle-invasive bladder cancer remains a significant clinical challenge, due in part to the highly aggressive nature of the ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
The US Food and Drug Administration has approved Johnson & Johnson’s drug delivery system for a type of bladder cancer, offering a potential surgery-free option for patients. The drug release system, ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® ...
It’s important to know what kinds of treatments are available for bladder cancer and understand that having a “tailored” treatment is important for patients, experts said. There are so many types of ...
Bladder cancer is a common cancer and one of the most costly to treat, yet there has been little change in the standard of care in 40 years. This panel will focus on the unmet needs in bladder cancer ...
A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology. High-risk non–muscle-invasive bladder ...
The National Institute for Health and Care Excellence (NICE) published draft guidance recommending avelumab (Bavencio, Merck Serono) for the treatment of certain forms of bladder cancer. Adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results